Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.44 |
| ▸ | HTR1A | P08908 | 7/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6895884 | 0.98 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HTR1AMPO | |
| Hydrochloric Acid SCHEMBL7694678 | 0.87 | MPO (0.46) | SLC6A2SLC6A4SLC6A3HTR1AMPO | |
| SCHEMBL21525054 | 0.84 | CHRNB2 (0.47) | MPOKCNH2HTR2C | |
| Hydrochloric Acid SCHEMBL28261072 | 0.83 | CHRNB2 (0.46) | MPOKCNH2HTR2C | |
| SCHEMBL8917899 | 0.82 | CYP11B1 (0.40) | SLC6A4 | |
| SCHEMBL4946723 | 0.82 | KCNH2 (0.42) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL20809217 | 0.82 | HTR2C (0.46) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| Hydrochloric Acid SCHEMBL20135194 | 0.81 | HTR2C (0.47) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL13584551 | 0.78 | SLC6A4 (0.55) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL14703963 | 0.77 | SLC6A4 (0.53) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115362151-B | Arylpiperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-21 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| EP-4126840-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115362151-A | Aryl piperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20220363679-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | US | disclosed |
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| WO-2021191384-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| EP-0794185-A1 | BICYCLIC THIAZOLE COMPOUND | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | SLC6A2 1095/4885SLC6A4 437/4885SLC6A3 588/4885 |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | SLC6A2 4833/4885SLC6A4 4748/4885SLC6A3 4639/4885 |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | SLC6A2 1095/4885SLC6A4 437/4885SLC6A3 588/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | SLC6A2 4812/4885SLC6A4 4698/4885SLC6A3 4571/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | SLC6A2 2418/4885SLC6A4 1958/4885SLC6A3 3425/4885 |
| US-20220363679-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | SLC6A2 1095/4885SLC6A4 437/4885SLC6A3 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.